Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Cream

Renowned Surgeon Examines Our Most Significant Contributions To Surgery - From Crude Procedures To Precision Operations
As a result of the scientific advances and medical innovations made in the twentieth century, the United States today occupies an established and unchallenged leading role in the field of surgery. Renowned surgeon Seymour I. Schwartz, MD, gives a sweeping history of American surgical practice in "Gifted Hands: America"s Most Significant Contributions To Surgery" (Prometheus Books). He describes how surgery in the United States has advanced from the comparatively crude practices of pioneering physicians in the pre-Columbian and colonial eras to its current level of preeminence in scientific surgery today.
generic viagra online
Xeloda In Combination With Oxaliplatin Shown To Be Effective In Early Colon Cancer
Roche announced results from the international phase III study NO16968 (XELOXA), investigating oral Xeloda in combination with intravenous oxaliplatin (XELOX) immediately after surgery, which show that patients with colon cancer taking XELOX live disease free for longer compared to those taking the commonly used intravenous chemotherapy combination 5-fluorouracil/leucovorin (5-FU/LV). The data prove that XELOX is superior to 5-FU/LV in terms of the time patients live without their cancer being detectable. Purchase zoloft to treat depression.
News of the day
Environmental Factors Instruct Lineage Choice Of Blood Progenitor Cells
The research team led by Dr. Timm Schroeder, stem cell researcher at Helmholtz Zentrum MÃønchen, has developed a new bioimaging method for observing the differentiation of hematopoietic progenitor cells (HPC) at the single-cell level. With this method the researchers were able to prove for the first time that not only cell-intrinsic mechanisms, but also external environmental factors such as growth factors can control HPC lineage choice directly. The findings, published in the current issue of the prestigious journal Science, provide an essential building block for understanding the molecular mechanisms of hematopoiesis and are an important prerequisite for optimizing therapeutic stem cell applications.
Public Health

5 Spanish Centers Join A Study For A New Leukemia And Lymphoma Treatment Technique

The Gamida Cell-Teva Joint Venture have today that five prestigious cord blood transplantation centers in Spain, three in Barcelona and two in Valencia, have joined the ExCell study. Participating clinical sites include, in alphabetical order: * Hospital Clç­nic of Barcelona, Barcelona: Principal Investigator, Dr. Enric Carreras, MD * Hospital Clç­nico Universitario de Valencia, Valencia: Principal Investigator, Dr. Cristina Arbona, MD * Hospital de la Santa Creu i Sant Pau, Barcelona: Principal Investigator, Dr. Jorge Sierra, MD * Hospital Germans Trias i Pujol, Barcelona: Principal Investigator, Dr. Christelle Ferra, MD * Hospital Universitario La Fe, Valencia: Principal Investigator, Dr. Guillermo Sanz, MD The trial is assessing the safety and efficacy of StemEx as a treatment for hematological malignancies, including leukemia and lymphoma, in a single arm, global, pivotal marketing authorization trial. StemEx is a graft of expanded stem/progenitor cells, derived from a single unit of umbilical cord blood and transplanted in combination with non expanded cells from the same unit. StemEx® is being developed by a Joint Venture of Gamida Cell and Teva Pharmaceutical Industries (NASDAQ: TEVA). ExCell is a study that gives clinicians the opportunity to explore a new path in the pursuit of a therapeutic treatment for patients with blood cancers. Cord blood can successfully be used to treat leukemia and lymphoma in young children. It stands to reason therefore that the same basic could also be used to effectively treat adolescents and adults. The ExCell trial provides an opportunity to determine if StemEx can indeed make this a possibility. Cord blood has less matching requirements than bone marrow or peripheral blood transplants, providing the potential to increase the number of suitable transplant matches and to shorten the time it can take to find a match. However, there are a limited number of stem/progenitor cells in cord blood, enabling a quantity sufficient generally only for pediatric treatment. StemEx® employs a technology that expands this small number of cord blood stem/progenitor cells, increasing their therapeutic capacity for transplantation in adolescents and adults. It is estimated that more than 11,000 patients in the European Union are in need of an allogeneic (from a outside of the patient"s body) hematopoietic (blood) stem cell transplantation. This is an unofficial figure calculated based on the method proposed by the US government"s General Accounting Office (GAO) report and The EBMT Activity Survey 2006 on Hematopoietic Stem Cell Transplantation: Focus on the Use of Cord Blood Products. "We are enthusiastic about working with these five outstanding hospitals in Spain, the esteemed principal investigators and their experienced staves. Together, we hope to demonstrate the advantage of the StemEx transplant for patients," said Dr. David Snyder, vice president of clinical development at Gamida Cell. Alex Argemi IDIBAPS - Institut d"Investigacions Biomç¨diques August Pi i Sunyer


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009